KRAS and pancreatic neoplasm: This workflow was adopted to quantitatively detect gene alterations, i.e., EWS rearrangements in Ewing sarcoma and total KRAS transcripts including both mutated KRAS and wild‐type KRAS in pancreatic cancer, allowing for noninvasive cancer diagnosis and treatment monitoring.